Evaluation of Cladribine treatment in refractory celiac disease type II.
about
Improving outcomes of refractory celiac disease - current and emerging treatment strategiesApproach to patients with refractory coeliac diseaseACG clinical guidelines: diagnosis and management of celiac diseaseSplenic volume differentiates complicated and non-complicated celiac diseaseChronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice.The management of refractory coeliac disease.An update on the management of peripheral T-cell lymphoma and emerging treatment optionsA 37-year-old woman with refractory coeliac disease type II disease treated by stem cell transplantation.Surgery in (pre)malignant celiac disease.Recognising and Managing Refractory Coeliac Disease: A Tertiary Centre ExperienceCeliac disease markers in patients with liver diseases: a single center large scale screening study.Update on the diagnosis and management of refractory coeliac disease.The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet.Hematopoietic stem cell transplantation for non-malignant gastrointestinal diseasesMechanisms and management of refractory coeliac disease.Current and novel therapeutic strategies in celiac disease.CD4 T-cell cytokines synergize to induce proliferation of malignant and nonmalignant innate intraepithelial lymphocytesLymphoma development and survival in refractory coeliac disease type II: Histological response as prognostic factor.Gluten sensitivities and the allergist: Threshing the grain from the husks.Refractory Celiac Disease Type II: A Case Report that Demonstrates the Diagnostic and Therapeutic Challenges.
P2860
Q26740769-3C537694-87DF-4BB6-AB3F-534D13EE572CQ28066895-ADC1475B-D358-49A0-8241-F9A5A9EE0182Q33457749-FB9565B2-F1C4-4464-881B-2E224B264A71Q33632969-C99C3AE0-B3EA-4367-86E0-1C52C3A2BAFDQ34441015-F766F16A-DDCC-43FA-8BD2-692CAB5F9B4AQ34650083-15775E1F-4651-4E85-B2F0-411A63ABEFF6Q35683871-022864C0-A558-4D21-9AC9-DCA08277B729Q35779375-373D4792-6B82-48CE-AFF4-DECB67EB55F0Q36290402-0C3B5FE6-E6FD-448D-BF6D-3909AB35C27BQ36401241-3FC11A68-FAE3-42D8-8AD2-1F7417EBFDDBQ36410388-A0C1843E-72FD-43A0-9CA5-5D5B639B6B77Q36879678-8F405E09-F5B5-452C-876E-20A03BDEC234Q38016781-2EBA5556-B2B1-43CE-81CC-FE2852F9837FQ38291498-D4D70D99-F72F-49ED-B351-F0DC837BCF62Q38582595-3E9D6228-0DDB-4B3F-AC45-BF7F707F99ECQ38870456-E4EAFBAE-3B05-43B5-BFE9-96247B2067C6Q39042122-5A532A03-B652-4154-AE8E-5D7DB1215B97Q40272954-C87042CC-F050-4605-88F6-47BC3634413FQ47409583-4171A8CC-DAC9-4743-A86C-DD517B26E951Q50979880-37FFE124-F663-4675-B3D5-EAAB6998F6EB
P2860
Evaluation of Cladribine treatment in refractory celiac disease type II.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Evaluation of Cladribine treatment in refractory celiac disease type II.
@ast
Evaluation of Cladribine treatment in refractory celiac disease type II.
@en
Evaluation of Cladribine treatment in refractory celiac disease type II.
@nl
type
label
Evaluation of Cladribine treatment in refractory celiac disease type II.
@ast
Evaluation of Cladribine treatment in refractory celiac disease type II.
@en
Evaluation of Cladribine treatment in refractory celiac disease type II.
@nl
prefLabel
Evaluation of Cladribine treatment in refractory celiac disease type II.
@ast
Evaluation of Cladribine treatment in refractory celiac disease type II.
@en
Evaluation of Cladribine treatment in refractory celiac disease type II.
@nl
P2093
P2860
P356
P1476
Evaluation of Cladribine treatment in refractory celiac disease type II.
@en
P2093
Abdul Al-Toma
Chris J J Mulder
Dirk J Kuik
Greetje J Tack
Marco W J Schreurs
Otto Visser
Wieke H M Verbeek
P2860
P304
P356
10.3748/WJG.V17.I4.506
P407
P577
2011-01-01T00:00:00Z